SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
QUANTECH LTD.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
74762K306
(CUSIP Number)
Thomas P. Livingston, Esq.
PE Corporation
761 Main Avenue
Norwalk, CT 06859
(203) 762-1000
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
November 4, 1999
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[ ].
NOTE. Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued on following pages)
Page 1 of 4 Pages
<PAGE>
CUSIP No. 74762K306 13D Page 2 of 4 Pages
<TABLE>
<S> <C> <C>
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
The Perkin-Elmer Corporation
06-0490270
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
3 SEC USE ONLY
4 SOURCE OF FUNDS*
WC, OO
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New York
NUMBER OF 7 SOLE VOTING POWER
SHARES 0
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 0
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 0
PERSON WITH 10 SHARED DISPOSITIVE POWER
0
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0
14 TYPE OF REPORTING PERSON
CO
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 4 Pages
<PAGE>
This Amendment No. 1 to Schedule D relating to shares of Common Stock,
par value $.01 per share (the "Issuer Common Stock"), of Quantech Ltd., a
Minnesota corporation (the "Issuer"), is being filed to report the fact that the
Reporting Person has ceased to beneficially own any shares of Issuer Common
Stock. Reference is made to the Initial Statement on Schedule 13D dated December
16, 1997 and filed by the Reporting Person with the Securities and Exchange
Commission on December 23, 1997 (the "Initial Statement") for information
regarding certain defined terms used but not otherwise defined herein. Items not
included in this Amendment No. 1 are either not amended or are not applicable.
Item 2. Identity and Background.
In connection with the recapitalization of Perkin-Elmer on May 6, 1999,
Perkin-Elmer became a wholly-owned subsidiary of PE Corporation, a Delaware
corporation ("PE"). The principal offices of PE are located at 761 Main Avenue,
Norwalk, Connecticut, 06859. PE conducts its business activities through its PE
Biosystems Group and its Celera Genomics Group.
The PE Biosystems Group is principally engaged in: (a) research,
development, manufacture, sale, and support of automated systems that
incorporate instruments, reagents, and software to facilitate research and
product development for the life sciences industry; and (b) related consulting
and contract research and development services. The Celera Genomics Group is
principally engaged in: (a) generation, sale, and support of genomic information
and related information management analysis software; (b) discovery, validation,
and licensing of proprietary gene products, genetic markers and information
concerning genetic variability; and (c) related consulting and contract research
and development services.
Item 5. Interest in Securities of Issuer.
(a), (b) As a result of the transaction described in Item 5(c),
Perkin-Elmer does not beneficially own any shares of Issuer Common Stock.
(c) Effective November 4, 1999, Perkin-Elmer and the Issuer entered
into an amendment to the License Agreement pursuant to which Issuer transferred
to Perkin-Elmer certain instruments, accessories, consumables, and technical
support in exchange for rights to certain intellectual property and the
termination of the Warrant and all rights thereunder. Except as set forth in the
immediately preceding sentence, there have not been any transactions in the
Issuer Common Stock effected by or for the account of Perkin-Elmer or, to the
knowledge of Perkin-Elmer, any of its directors or executive officers, during
the past 60 days.
(d) Not applicable.
Page 3 of 4 Pages
<PAGE>
(e) Effective November 4, 1999, the Reporting Person ceased to be the
beneficial owner of more than 5% of the Issuer Common Stock.
Item 6. Contracts, Arrangements, Undertakings or Relationships with Respect to
Securities of the Issuer.
See Item 5(c) above.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
THE PERKIN-ELMER CORPORATION
By: /s/ Thomas P. Livingston
--------------------------------------
Thomas P. Livingston
Assistant Secretary
Dated: November 12, 1999
Page 4 of 4 Pages
